Jul 02

Bortezomib-based treatment improves survival in patients with cardiac amyloidosis

First-line treatment with the proteasome inhibitor bortezomib (Velcade, Millennium Pharmaceuticals) plus dexamethasone and an alkylating agent (BDex+AA) improves survival in patients with symptomatic heart failure due to amyloid light-chain (AL) amyloidosis, a rapidly fatal disease. After multivariable adjustment, patients receiving BDex+AA as their initial regimen had a 20% lower mortality risk than those receiving other regimens (hazard ratio 0.20). These findings are published in the June 28, 2016 issue of the Journal of the American College of Cardiology

Jul 01

FDA Advisory Committee narrowly okay empagliflozin cardiovascular mortality claim

The Endocrinologic and Metabolic Drugs Advisory Committee voted 12-11 on June 28 that the data in the EMPA-REG OUTCOME study provided substantial evidence to establish that empagliflozin, sodium-glucose cotransporter-2 (SGLT-2), reduced cardiovascular mortality in the population studied, those with type 2 diabetes and established cardiovascular disease.

Jun 28

Efficacy of pioglitazone in preventing diabetes and improving cardiovascular outcomes

According to a study presented at the 76th Scientific Sessions of the ADA and published in The New England Journal of Medicine, pioglitazone showed its efficacy in reducing the risk of type 2 diabetes by 52% in non-diabetic (especially individuals with pre-diabetes), insulin-resistant people with Cerebrovascular disease. The investigators stated that pioglitazone appears to be the only hypoglycemic agent that not only helps in preventing the occurrence of diabetes but also ameliorates cardiovascular outcomes.

Jun 28

Impact of alogliptin therapy on cardiovascular events in type 2 diabetes

The researchers conducted a post-hoc analysis of the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care (EXAMINE) trial which revealed that the use of alogliptin, a dipeptidyl peptidase-4 inhibitor was not associated with cardiovascular-related mortality in patients with type 2 diabetes mellitus who experienced acute coronary syndrome. In addition, it did not cause any non-fatal cardiovascular event in comparison with placebo in this patient population. They stated that this drug reduces blood glucose concentrations by delaying the inactivation of incretin hormones that are responsible for stimulating the release of insulin from the pancreas, findings printed in the journal of Diabetes Care.

Jun 21

Lower BP goals are better for elderly

Among ambulatory adults aged 75 years or older, treating to a systolic blood pressure target of less than 120 mm Hg (intensive control) compared with a systolic blood pressure target of less than 140 mm Hg (standard control) resulted in 34% relatively lower risk of fatal and nonfatal major cardiovascular events and death from cardiovascular causes. Similar, death from any cause also reduced by 33% over a median follow-up of 3.14 years. The study is reported online May 19,2016 in the Journal of the American Medical Association.

Jun 20

 High consumption of sugar-sweetened carbonated beverages associated with increased CAC

Results of a large cross-sectional study of 22,210 asymptomatic men and women published in the July 2016 issue of the American Heart Journal show that high levels of sugar-sweetened carbonated beverage consumption are associated with a higher prevalence and degree of coronary artery calcium (CAC) in asymptomatic adults without a history of cardiovascular disease, cancer, or diabetes.

Jun 17

Diastolic orthostatic HT associated with decreased risk for incident cardiovascular events

According to a prospective cohort study published June 2, 2016 in the journal Cardiovascular Diabetology, diastolic orthostatic hypertension (HT) is common in patients with type 2 diabetes, and may be a novel marker for decreased cardiovascular risk in these patients. Diastolic orthostatic hypotension was found in 4.1 % in the study and it was associated with higher values for aortic pulse wave velocity and carotid intima-media thickness vs patients with normal systolic and diastolic orthostatic blood pressure response. However, the authors suggest to repeat the measurement on several occasions in order to enhance the prognostic performance.

Jun 14

Cardiovascular mortality is higher in patients with type 2 diabetes and recent ACS

A post hoc analysis of the Examination of Cardiovascular Outcomes With Alogliptin versus Standard of Care (EXAMINE) trial with the type 2 diabetes drug alogliptin (Nesina, Takeda), an oral dipeptidyl peptidase–4 (DPP-4) inhibitor, has shown that the risk of cardiovascular death was higher if patients in the trial had first experienced a nonfatal cardiovascular event, particularly heart failure, compared with those who did not experience a CV event. The study is published online June 11, 2016 in Diabetes Care.

Jun 13

Early removal of Nanostim leadless pacemaker is safe

A new research presented June 8, 2016 at the recent European Heart Rhythm Association (EHRA) EUROPACE-CARDIOSTIM 2016 meeting in Nice, France has shown that it is feasible and safe to remove the Nanostim leadless pacemaker (St Jude Medical) up to 3.2 years after implantation. The procedural success rate was 93.3% among 15 patients who underwent a retrieval attempt at a mean of 256 days (range 1–1188 days) at 12 centers with 12 different operators.

Jun 13

Early removal of Nanostim leadless pacemaker is safe

A new research presented June 8, 2016 at the recent European Heart Rhythm Association (EHRA) EUROPACE-CARDIOSTIM 2016 meeting in Nice, France has shown that it is feasible and safe to remove the Nanostim leadless pacemaker (St Jude Medical) up to 3.2 years after implantation. The procedural success rate was 93.3% among 15 patients who underwent a retrieval attempt at a mean of 256 days (range 1–1188 days) at 12 centers with 12 different operators.

Older posts «

» Newer posts


Fatal error: Internal zval's can't be arrays, objects or resources in Unknown on line 0